Join
Live feed
·
PRReleasevia Quantisnow
Structure Therapeutics Inc. logo

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

ByQuantisnow·Wall Street's wire, on your screen.
GPCR· Structure Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GPCR (Structure Therapeutics Inc.) and more on Quantisnow.